Gamma-tocopherol supplementation alone and in combination with alpha-tocopherol alters biomarkers of oxidative stress and inflammation in subjects with metabolic syndrome.
Metabolic syndrome (MetS) is associated with increased incidence of diabetes and cardiovascular disease (CVD). Prospective clinical trials with alpha-tocopherol (AT) have not yielded positive results. Because AT supplementation decreases circulating gamma-tocopherol (GT), we evaluated supplementation with GT (800 mg/day), AT (800 mg/day), the combination or placebo for 6 weeks alone AT and GT concentrations, biomarkers of oxidative stress, and inflammation in subjects with MetS (n=20/group). Plasma AT and GT levels increased following supplementation with AT alone or GT alone or in combination. AT supplementation significantly decreased GT levels. Urinary alpha- and gamma-CEHC, metabolites of the respective Ts, also increased correspondingly, i.e., alpha-CEHC with AT and gamma-CEHC with GT supplementation, compared to placebo. HsCRP levels significantly decreased in the combined AT+GT group. LPS-activated whole blood release of IL-1 and IL-6 did not change. There was a significant decrease in TNF with AT alone or in combination with GT. Plasma MDA/HNE and lipid peroxides were significantly decreased with AT, GT, or in combination. Nitrotyrosine levels were significantly decreased only with GT or GT+AT but not with AT compared to placebo. Thus, the combination of AT and GT supplementation appears to be superior to either supplementation alone on biomarkers of oxidative stress and inflammation and needs to be tested in prospective clinical trials to elucidate its utility in CVD prevention.
Devaraj
Sridevi
S
Laboratory for Atherosclerosis and Metabolic Research, Department of Pathology and Laboratory Medicine, UC Davis Medical Center, Sacramento, CA 95817, USA. sridevi.devaraj@ucdmc.ucdavis.edu
Leonard
Scott
S
Traber
Maret G
MG
Jialal
Ishwarlal
I
D000447:Aldehydes / Q000097:blood; D015415:Biomarkers / Q000032:analysis / Q000378:metabolism; D002097:C-Reactive Protein / Q000187:drug effects / Q000378:metabolism; D019587:Dietary Supplements; D004311:Double-Blind Method; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007249:Inflammation / Q000517:prevention & control*; D007375:Interleukin-1 / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D008054:Lipid Peroxides / Q000097:blood; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D024821:Metabolic Syndrome / Q000503:physiopathology*; D008875:Middle Aged; D018384:Oxidative Stress / Q000187:drug effects*; D010919:Placebos; D014409:Tumor Necrosis Factor-alpha / Q000097:blood / Q000187:drug effects; D014815:Vitamins / Q000494:pharmacology*; D024502:alpha-Tocopherol / Q000378:metabolism / Q000494:pharmacology*; D024504:gamma-Tocopherol / Q000378:metabolism / Q000494:pharmacology*
D000447:Aldehydes; D015415:Biomarkers; D007375:Interleukin-1; D015850:Interleukin-6; D008054:Lipid Peroxides; D010919:Placebos; D014409:Tumor Necrosis Factor-alpha; D014815:Vitamins; C462359:tert-4-hydroxy-2-nonenal; D008315:Malondialdehyde; D024504:gamma-Tocopherol; D002097:C-Reactive Protein; D024502:alpha-Tocopherol